𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Human leukocyte antigen class II and III alleles and severity of hepatitis C virus–related chronic liver disease

✍ Scribed by Margherita Asti; Miryam Martinetti; Claudo Zavaglia; Maria Clara Cuccia; Laura Gusberti; Carmine Tinelli; Agostino Cividini; Savino Bruno; Laura Salvaneschi; Gaetano Ideo; Mario U. Mondelli; Enrico M. Silini


Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
100 KB
Volume
29
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis


Hepatitis C outcome is likely related both to viral factors and host's immune responses. We correlated the severity of liver disease with human leukocyte antigen (HLA) genes (C4A, C4B, TNFA, TNFB, DRB1, DRB3, DRB4, DRB5, DQA1, DQB1, TAP1, and TAP2) in three groups of subjects: 99 patients with chronic hepatitis, 41 asymptomatic carriers, and 179 uninfected controls. Patients with grade/stage 3 to 4 hepatitis significantly differentiated for their low frequency of alleles TNFB*1, DRB1*1104, and DRB3*03, which had a protective role, and high frequency of allele DRB1*1001, which was associated with disease severity. HLA-DRB*11 subtypes were differentially distributed: DRB1*1104 was most frequent in carriers, whereas DRB1*1101 was more frequent in patients. The TAP1C,2A haplotype was also underrepresented in patients with respect to controls. Finally, a decrease of heterozygous subjects was observed in patients with respect to carriers at the DQB1 locus. Multivariate analysis by correspondence analysis and multiple logistic regression indicated that age, sex, and hepatitis C virus (HCV) type were the strongest risk factors; however, some immunogenetic variables (TNFB*1, DRB1*1104, and DRB3*03) showed an independent contribution, especially in comparing patients with extreme manifestations of disease. The involvement of different genes in various HLA subregions suggests that anti-HCV responses are modulated by a complex gene interplay rather than by single alleles.


📜 SIMILAR VOLUMES


Specific human leukocyte antigen class I
✍ Mark H. Kuniholm; Andrea Kovacs; Xiaojiang Gao; Xiaonan Xue; Darlene Marti; Chlo 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB 👁 1 views

Studies of human leukocyte antigen (HLA) alleles and their relation with hepatitis C virus (HCV) viremia have had conflicting results. However, these studies have varied in size and methods, and few large studies assessed HLA class I alleles. Only one study conducted high-resolution class I genotypi

Urinary transforming growth factor β1 le
✍ J Tsai; J Jeng; L Chuang; W Chang; J Tsai 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 206 KB

To assess the clinical relevance of transforming growth factor beta1 (TGF-beta1) in chronic liver disease, urinary TGF-beta1 and circulating aminoterminal propeptides of type III procollagen (PIIINP) levels were determined by radioimmunoassay in 100 cirrhotic patients, 44 patients with chronic hepat

Human leukocyte antigen class II associa
✍ Rebecca A. Harris; Kazushi Sugimoto; David E. Kaplan; Fusao Ikeda; Malek Kamoun; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 370 KB 👁 1 views

The outcome of hepatitis C virus (HCV) infection has been associated with antiviral CD4 T cell response, human leukocyte antigens (HLA) class II genotypes, and ethnicity. However, HLA class II molecules restrict the nature of CD4 T cell response, and HLA distributions differ between ethnic groups. I

Genetic variability of hepatitis C virus
✍ F. Xavier López-Labrador; Marina Berenguer; Amparo Sempere; Martín Prieto; Rafae 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 200 KB 👁 1 views

The association between the severity of chronic hepatitis C and the variability of the hepatitis C virus (HCV) genome remains controversial, but to our knowledge few data are available to date regarding T-cell epitope coding regions in transplant patients. In the current study, we identified 21 huma

Clinical progression of hepatitis C viru
✍ Juan A. Pineda; José A. García-García; Manuela Aguilar-Guisado; María J. Ríos-Vi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 311 KB 👁 2 views

Little is known about the natural history of liver disease in human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected subjects under highly active antiretroviral therapy (HAART). The objectives of this study were to obtain information about the mortality, the incidence of hepatic decom

Killer cell immunoglobulin-like receptor
✍ Alejandro Espadas de Arias; Simone Elizabeth Haworth; Luca Saverio Belli; Patriz 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB

In 20% to 30% of infected individuals, hepatitis C virus (HCV) can cause cirrhosis and hepatocellular carcinoma, for which liver transplantation is the best treatment available. HCV re-infection is universal, and hepatitis disease recurrence occurs in most cases with a 30% probability of progression